medwireNews: Pathologic complete response (pCR) is significantly associated with 5-year survival outcomes for early-stage breast cancer patients with hormone receptor (HR)-positive, HER2-positive disease, shows research reported at the ESMO Virtual Congress 2020.
ADAPT-TP trial findings previously indicated that patients given neoadjuvant trastuzumab emtansine (T-DM1) alone or alongside endocrine therapy (ET) were significantly more likely to achieve pCR than those given trastuzumab plus ET, at 41.0%, 41.5%, and 15.1 %, respectively, explained Nadia Harbeck (Ludwig Maximilians University Hospital-Grosshadern, Munich, Germany).
The trial update showed that, after a median 60.5 months, patients with pCR at their 12-week biopsy were significantly more likely to achieve 5-year disease-free survival (DFS) than those who did not, at 92.7% versus 82.7%.
But Harbeck noted that 5-year rates of DFS, distant DFS, and overall survival were comparable between the three treatment arms, “most likely due to the additional administration of standard chemotherapy in all patients without pCR and in the majority, that is 65%, of patients with pCR.”
Describing the ADAPT-TP trial survival outcomes as “excellent,” the presenter suggested the study “demonstrates [the] feasibility and safety of early pCR-guided trials for therapy de-escalation in HER2-positive early breast cancer.”
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group